PRF Technologies (PRFX) Cash from Investing Activities (2021 - 2024)
PRF Technologies' (PRFX) quarterly Cash from Investing Activities came in at -$5000.0 in Q2 2024, up 99.5% YoY from -$2506.3 in Q3 2023, and up 28.57% on a QoQ basis from -$7000.0 in Q1 2024.
PRF Technologies (PRFX) Cash from Investing Activities (2021 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 4 years of Cash from Investing Activities data on file, last reported at -$5000.0 in Q2 2024.
- Quarterly Cash from Investing Activities rose 99.5% year-over-year to -$5000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $979000.0 (up 197.61% YoY) and the FY2025 annual result came in at -$982000.0, down 7453.85% from the prior year.
- Cash from Investing Activities rose to -$5000.0 in Q2 2024, from -$7000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $22.0 million in Q4 2021 to a low of -$22.0 million in Q3 2021.
- A 4-year average of -$6166.7 and a median of -$6000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 3467.86% — and 2024, when it slumped 100.12%.
- Tracing PRFX's Cash from Investing Activities over 4 years: stood at $22.0 million in 2021, then plunged by 99.87% to $28000.0 in 2022, then surged by 3467.86% to $999000.0 in 2023, then plunged by 100.5% to -$5000.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$5000.0 (Q2 2024), -$7000.0 (Q1 2024), and $999000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Jun 30, 2023 | -1.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | 6.00 Mn |
| Mar 31, 2023 | 6.00 Mn |
| Dec 31, 2022 | 28,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | -6.03 Mn |
| Sep 30, 2022 | -6.03 Mn |
| Dec 31, 2021 | 21.95 Mn |
| Dec 31, 2021 | 21.95 Mn |
| Sep 30, 2021 | -21.98 Mn |
| Sep 30, 2021 | -21.98 Mn |